ReviewFrontiers in immunology2022
CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 58 citations in OpenAlex.
- CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review.Biomolecules & biomedicine · 2026Review
- Vitamin C Conditioning Generates Tumor-Targeting CAR T Cells with Superior Cytotoxicity and Fitness in a Posttransplant Lymphoproliferative Disorder Tumor Model.Molecular cancer therapeutics · 2026Article
- Establishment of a serum-free culture system with an optimized 5-interleukin cytokine cocktail and insulin to promote preferential CD8⁺ T-cell expansion.Bioprocess and biosystems engineering · 2026Article
- CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management.Translational oncology · 2026Article
- Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.Stem cell reviews and reports · 2026Review
- Redefining cell therapy: CAR-engineered innate immune cells to conquer solid and hematologic malignancies.Molecular biology reports · 2026Review
- Spectrum and prognosis of CAR-T-related endocrine toxicity: glucose/calcium dysregulation, pituitary axis disorders, and overlap with CRS.Frontiers in medicine · 2026Article
- CD19-negative relapse after CAR-T cell therapy: mechanisms of antigen escape and lineage switch.Frontiers in immunology · 2026Review
- Advances in Biomarkers for CAR-T Treatment Resistance in Diffuse Large B-Cell Lymphoma.Mini reviews in medicinal chemistry · 2026Review
- CRISPR/Cas9 Technology for Modifying Immune Checkpoint in CAR-T Cell Therapy for Hematopoietic Malignancies.Current gene therapy · 2026Review
- Imaging the fate of CAR-T cellsFrontiers in immunology · 2026Review
- Emerging Chimeric Antigen Receptor-Immune Cell Therapy for Pancreatic Cancer: Mechanisms, Clinical Advances, and Future Perspectives.Oncology research · 2026Review
- HLA-G in Hematological Malignancies: Immunoregulatory Mechanisms and Implications for Immune Evasion and Immunotherapy.Journal of immunology research · 2026Review
- Current Status of Molecularly Targeted Therapeutics in Blood Cancers.International journal of molecular sciences · 2025Review
- Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction.International journal of molecular sciences · 2025Review
- Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer.Clinical and experimental medicine · 2025Review
- From lab to lifesaver: the rise of CAR T-cell therapy in oncology.Journal of the Egyptian National Cancer Institute · 2025Review
- Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.Current issues in molecular biology · 2025Review
- TIGIT/PVR axis regulates anti-tumor immunity in hematologic malignancies.Annals of hematology · 2025Review
- From TCR fundamental research to innovative chimeric antigen receptor design.Nature reviews. Immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past decade, the emergence of chimeric antigen receptor (CAR) T-cell therapy has led to a cellular immunotherapy revolution against various cancers. Although CAR-T cell therapies have demonstrated remarkable efficacy for patients with certain B cell driven hematological malignancies, further studies are required to broaden the use of CAR-T cell therapy against other hematological malignancies. Moreover, treatment failure still occurs for a significant proportion of patients. CAR antigen loss on cancer cells is one of the most common reasons for cancer relapse. Additionally, immune evasion can arise due to the hostile immunosuppressive tumor microenvironment and the impaired CAR-T cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.